Genome-wide association studies (GWAS) have identified four susceptibility loci for epithelial ovarian cancer (EOC), with another two suggestive loci reaching near genome-wide significance. We pooled data from a GWAS conducted in North America with another GWAS from the UK. We selected the top 24,551 SNPs for inclusion on the iCOGS custom genotyping array. We performed follow-up genotyping in 18,174 individuals with EOC (cases) and 26,134 controls from 43 studies from the Ovarian Cancer Association Consortium. We validated the two loci at 3q25 and 17q21 that were previously found to have associations close to genome-wide significance and identified three loci newly associated with risk: two loci associated with all EOC subtypes at 8q21 (rs11782652, P = 5.5 × 10 −9 ) and 10p12 (rs1243180, P = 1.8 × 10 −8 ) and another locus specific to the serous subtype at 17q12 (rs757210, P = 8.1 × 10 −10 ). An integrated molecular analysis of genes and regulatory regions at these loci provided evidence for functional mechanisms underlying susceptibility and implicated CHMP4C in the pathogenesis of ovarian cancer.
Evidence from twin and family studies suggests an inherited genetic component to EOC risk 1, 2 . Rare, high-penetrance alleles of genes such as BRCA1 and BRCA2 account for about 40% of excess familial risk 3 , and GWAS have recently identified common risk alleles at 9p22, 8q24, 2q31 and 19p13 (refs. 4-6) , with two additional loci at 3q25 and 17q21 that approached genome-wide significance 6 . However these alleles only explain 4% of excess familial risk, and more risk loci probably exist.
We therefore pooled the data from two GWAS to inform the selection of SNPs for a large-scale replication. The North American study comprised 4 independent case-control studies that included 1,952 cases and 2,052 controls. The second study was a 2-phase multicenter GWAS that included 1,817 cases and 2,354 controls in the first phase and 4,162 cases and 4,810 controls in the second phase. We carried out a fixed-effects meta-analysis from the two GWAS for ~2.5 million genotyped or imputed SNPs. We selected 24,551 SNPs associated with the risk of either all-histology (11, 647 SNPs) or serous (12, 904 SNPs) ovarian cancer on the basis of ranked P values. We designed assays for 23,239 SNPs and included them on a custom Illumina Infinium iSelect array (iCOGS) comprising 211,155 SNPs designed by the Collaborative Oncological Gene-environment Study (COGS) to evaluate genetic variants for association with risk of breast, ovarian and prostate cancers. We then genotyped these SNPs in cases and controls from 43 individual studies from the Ovarian Cancer Association Consortium (OCAC) that were grouped into 34 case-control strata ( Table 1 and Supplementary Tables 1 and 2) . These included most of the samples genotyped in the initial GWAS.
RESULTS

Association analyses
After applying quality control filters (Online Methods), we tested 22, 252 SNPs for association with risk of all subtypes of invasive EOC and serous invasive EOC in 18,174 cases (including 10,316 with the serous subtype) and 26,134 controls. Primary analyses were based on data from the subjects of European ancestry (16, 283 cases and 23,491 controls).
We confirmed associations of the four SNPs at 2q31, 8q24, 9p22 and 19p13 that were previously reported at genome-wide significance ( Supplementary Table 3 ). We also confirmed SNPs at the two other loci previously reported as being near genome-wide significance (at 3q25 and 17q21) 6 . The previously reported associated SNP at 3q25 (rs2665390) 6 failed design, but a correlated SNP, rs7651446 (r 2 = 0.61), was highly significantly associated with invasive EOC (effect allele frequency = 0.050, per-allele odds ratio (OR) = 1.44, 95% confidence interval (CI) = 1.35-1.53, P = 1.5 × 10 −28 ), as was rs9303542 at 17q21 (effect allele frequency = 0.27, OR = 1.12, 95% CI = 1.08-1.16, P = 6.0 × 10 −11 ). We generated Manhattan plots for all subtypes of invasive EOC and serous invasive EOC after excluding 176 SNPs from the 6 known loci ( Fig. 1) . We identified three new loci associated at genome-wide significance (P < 5 × 10 −8 ), two of which were significant for all subtypes of invasive EOC (8q21 and 10p12) and another that was significant for invasive serous EOC only (17q12) ( Table 2) . Genotype clusters for the top hits at 8q21 (rs11782652) and 17q12 (rs757210) were distinct, but clusters for the top hit at 10p12 (rs7084454) overlapped ( Supplementary Fig. 1 ). Clusters for a second, highly correlated SNP (r 2 = 0.86) at this locus (rs1243180) were distinct, and so the results for this SNP are presented instead.
The most significant association for all subtypes of invasive EOC was rs11782652 at 8q21 (OR = 1.19, 95% CI = 1.12-1.26, P = 5.5 × 10 −9 ). We selected this SNP for replication because it was associated with all subtypes of invasive EOC in the combined GWAS data (OR = 1.20, 95% CI = 1.07-1.36, P = 0.0025). This SNP is not correlated with any other SNP in HapMap (Supplementary Fig. 2) and was the only SNP in the region selected for genotyping in COGS. Effects varied by histological subtype (P = 0.0002), with the strongest effect seen in the serous subtype ( Table 2) . There was little evidence for heterogeneity in the association by ancestry (P = 0.55) or between the 31 European studies included (P = 0.13; Supplementary Fig. 3 ). We selected rs1243180 at 10p12 for replication because it was associated with all subtypes of invasive EOC in the combined GWAS data (OR = 1.11, 95% CI = 1.04-1.19, P = 0.0027) and was also associated with risk of all subtypes of invasive EOC in the replication data (OR = 1.10, 95% CI = 1.06-1.13, P = 1.8 × 10 −8 ). There is strong linkage disequilibrium in this region, and we selected 32 other SNPs in the region for replication ( Supplementary  Fig. 4 ). There was some heterogeneity of effects by tumor subtype (P = 0.0007) but not by study (P = 0.65; Supplementary Fig. 5 ) or population (P = 0.12). At 17q12, we selected rs757210 for replication because it was associated with serous EOC in the combined GWAS data (OR = 1.13, 95% CI = 1.04-1.23, P = 0.0026) and was most strongly associated with the serous subtype in the replication data (OR = 1.12, 95% CI = 1.08-1.17, P = 9.6 × 10 −10 ). We selected eight other SNPs in the region for replication in COGS ( Supplementary Fig. 6 ). The association with all invasive subtypes of EOC was much weaker in this analysis (OR = 1.05, 95% CI = 1.02-1.09, P = 9 × 10 −4 ); there was substantial heterogeneity by tumor subtype (P ≤ 0.0001), with the risk allele for serous EOC being associated with a reduced risk of both clear-cell and mucinous EOC ( Table 2) . Data from a set of fine-mapping SNPs genotyped in this region suggest that this apparent paradox is caused by the presence of two independent loci for serous and clear-cell cancer and that the top hit at each of these loci is correlated with rs757210 (ref. 7). There was also heterogeneity by ancestry for the serous subtype (P = 0.034), with the risk allele being associated with lower disease risk in subjects of mixed ancestry and the presence of some between-study heterogeneity (P = 0.038; Supplementary Fig. 7 ).
Functional and molecular analyses
The most significant risk-associated SNPs for the three new EOC susceptibility loci are located in noncoding DNA sequences, but these may be only markers for the true causal variants, which could be functional coding variants or variants in noncoding DNA elements or noncoding RNAs and might influence the expression of nearby target genes (cis-regulatory effects). They may also act on genes through more distal regulation (trans-regulatory effects) [8] [9] [10] [11] [12] . To identify the possible functional SNP and target gene for each locus, we evaluated the putative functional role in EOC for all genes in a 1-Mb region centered on the most significant risk-associated SNP. We used a combination of locus-specific and genome-wide assays to characterize the transcribed genes (Online Methods and Supplementary Fig. 8 ) and regulatory elements ( Supplementary Fig. 9 ) within susceptibility regions to evaluate putative functional mechanisms and identify candidate EOC susceptibility gene(s) at each locus.
At the 8q21 locus, the strongest associated SNP, rs11782652, is located in the first intron of CHMP4C. We imputed genotypes in the region to 1000 Genomes Project data and tested all variants with minor allele frequency (MAF) > 0.02 for association. We compared the log likelihoods of the regression models and considered eight SNPs with a log likelihood within 6.91 of the most strongly associated SNP (equivalent to odds of 1,000:1) as the possible candidates for the causal variant. Six of these SNPs lie in introns of CHMP4C, but in silico analysis provided functional evidence for only one (rs74544416), which contains a putative SOX9 binding site. One SNP is an indel (4 nt) at the exon-intron border (rs137960856, alleles -/GTGA), but it is unlikely to have a functional impact because the next four nucleotides are also GTGA. Thus, even in the deleted allele, the corrected exonic sequences are retained, and this SNP is not expected to affect splicing. The eighth SNP, rs35094336, is predicted to result in a coding change from alanine to threonine that may be functionally relevant (PolyPhen-2 score of 0.997). This residue is located in a C-terminal amphipathic α helix that is conserved in all CHMP4 proteins and is important for binding to ALIX, a protein that is involved in the endosomal sorting complex required for transport 13 . Further studies will be necessary to determine whether this change is of functional relevance and has an impact on ovarian cancer biology. Encyclopedia of DNA Elements (ENCODE) data from tissues not associated with ovarian cancer, formaldehyde-assisted isolation of regulatory elements sequencing (FAIRE-seq) data and mapping of enhancer elements generated in normal serous ovarian cancer precursor A r t i c l e s cells suggested that there are two regulatory regions that may be influenced by risk-associated SNPs: one at the CHMP4C promoter and the other in intron 1 of CHMP4C (Fig. 2) .
We found no evidence of a correlation between rs11782652 genotype and gene expression in normal ovarian or fallopian tube epithelial cells for any of the nine genes in the region (FABP5, PMP2, FABP4, FABP12, IMPA1, SLC10A5, ZFAND1, CHMP4C and SNX16), but there was a highly statistically significant association between rs11782652 and CHMP4C expression in primary EOC tissues (P = 3.9 × 10 −14 ) and transformed lymphocytes (P = 0.012). We also found evidence of association for rs11782652 with methylation status (methylation quantitative trait locus (mQTL)) for three genes in tumor tissue ( Supplementary Table 4 ): ZFAND1 (P = 0.003), CHMP4C (P = 0.001) and SNX16 (P = 0.001). However, gene methylation was only correlated with gene expression for CHMP4C.
Three genes in the region, FABP5, CHMP4C and SNX16, were significantly overexpressed in both EOC cell lines compared to in normal tissues (P = 0.002, P = 4.8 × 10 −9 and P = 5.9 × 10 −4 , respectively; Supplementary Table 5 ) and, where data were available, in primary EOC tissues. The Catalogue of Somatic Mutations in Cancer (COSMIC) database showed that four genes in the region, IMPA1, ZFAND1, CHMP4C and SNX16, have functionally relevant mutations in cancer, with the last three genes found to be mutated in ovarian carcinoma ( Supplementary Fig. 10 ). These four genes formed a highly connected coexpression network across different experimental conditions ( Supplementary Fig. 11 ).
Taken together, these data suggest that several genes at the 8q21 locus may have a role in the somatic development of EOC; however, the cumulative evidence indicates that CHMP4C (encoding chromatinmodifying protein 4C) is the probable candidate susceptibility gene. This is supported by previously published data on the function of CHMP4C. CHMP4C is involved in the final steps of cell division, coordinating midbody resolution with the abscission checkpoint 14 , and its transcription is regulated by TP53 to enhance exosome production 15 . A more recent study has shown that CHMP4C is frequently overexpressed in ovarian tumor tissues, with the suggestion that it may be a diagnostic tumor marker and therapeutic target for patients with the disease 16 .
At the 10p12 locus, six known genes (NEBL, C10orf113, C10orf114, SKIDA1 (also known as C10orf140), MLLT10 and DNAJC1) span the 1-Mb region around rs1243180, which lies in an intron of MLLT10 (Fig. 3) . On the basis of data imputed from the 1000 Genomes Project, 57 SNPs are candidates as functionally relevant variants. This includes variants in the 3′ UTR of C10orf114 and the 5′ UTR of SKIDA1 and a synonymous variant in MLLT10. Forty-six SNPs lie in introns of MLLT10, and the remaining eight are intergenic. In silico analyses found little or no evidence that any of these SNPs, including the most highly risk-associated SNP, rs1243180, are functional. However, after FAIRE-seq analysis of normal serous ovarian cancer precursor cells, we found one of these SNPs, rs10828252 (r 2 = 0.87 with rs1243180), to coincide with a region of open chromatin, which probably corresponds to the promoter of MLLT10 (Fig. 3) . Although rs10828252 is not positioned directly at the apex of the signal and is instead within the upstream portion, it is well established that open chromatin at the transcriptional start sites of genes results from the coordinated influence of numerous transcription factors binding within the vicinity; therefore, it is highly plausible that rs10828247 is modulating one of these transcription factor binding sites. The resulting shape and position of the FAIRE-seq signal may therefore represent the resulting effects of putative transcription factor binding at rs10828247 working in concert with binding at other sites in close proximity.
This finding suggests a possible mechanism for susceptibility to EOC at this locus through subtle variations in the promoter regulation of MLLT10. However, expression quantitative trait locus (eQTL) analysis found no significant association between the genotype of either rs1243180 or rs10828252 and MLLT10 expression in normal tissues. We did observe eQTL associations for two other coding genes in the region, NEBL (P = 0.04) and C10orf114 (P = 0.03). C10orf114 expression was also associated with rs1243180 genotype in primary EOC tissues (P = 0.02), as was SKIDA1 (P = 0.02). Methylation at both SKIDA1 and MLLT10 was associated with rs1243180 genotype in primary EOC tissues (P = 0.03 and 0.05, respectively), and both genes showed a significant negative correlation between methylation and expression (P = 0.0016 and 0.002, respectively). SKIDA1 also showed a significant difference in methylation in tumors compared to normal tissue (P = 1.9 × 10 −5 ).
Four genes (NEBL, C10orf114, SKIDA1 and MLLT10) were significantly overexpressed in EOC cell lines compared to in normal tissues (P ≤ 0.01), two of which (C10orf114 and MLLT10) also showed overexpression in primary EOC tissues (Fig. 3) . Correlations between gene expression and DNA copy number variation at this locus in primary EOC tissues suggest that overexpression of C10orf114 and MLLT10 is driven by copy number variation. NEBL is the only gene with reported mutations in ovarian cancer (Supplementary Fig. 10 ). Together, these data suggest that NEBL, C10orf114, SKIDA1 and MLLT10 might all npg have a role in ovarian cancer development, and any of these four genes could be the target susceptibility gene at this locus. However, there is no other evidence to implicate C10orf114 or SKIDA1 in EOC or to suggest a functional mechanism that may underlie disease susceptibility.
More is known about the functions of NEBL and MLLT10, although neither gene has previously been implicated in ovarian cancer. MLLT10 (mixed-lineage leukemia (trithorax homolog, Drosophila) translocated to 10) encodes a transcription factor and has been identified as a partner gene that is involved in several chromosomal rearrangements that result in leukemia 17 Figures 8 and 9 for additional molecular analyses of all genes at this locus. H3K4me1, methylation of histone H3 at Lys4; H3K27ac, acetylation of histone H3 at Lys27; H3K3me3, trimethylation of histone H3 at Lys3. npg A r t i c l e s been described at the molecular level, including the recently reported fusion NEBL-MLL 18 . NEBL (nebulette) encodes a nebulin-like protein that is abundantly expressed in cardiac muscle and has been implicated in the genetics of sudden cardiac death syndrome and cardiac remodeling 19 . This evidence does not directly support a role for these genes in ovarian cancer, but the first common gene fusion in serous ovarian cancers (ESRRA-TEX40 (also known as C11orf20)) was recently reported and provides an underlying hypothesis for the involvement of genes at this locus in EOC development 20 .
At chromosome 17q12, the most significantly associated SNP, rs757210, lies in an intron of HNF1B and is associated with the serous subtype of ovarian cancer. On the basis of data imputed from the 1000 Genomes Project, nine SNPs are candidates as the causal variant. SNPs in this region have been associated with diabetes 21 , endometrial cancer 22 and prostate cancer 23 . There are 13 genes in the 500-kb regions on either side of this SNP (ACACA, C17orf78, TADA2A (also known as TADA2L), DUSP14, SYNRG (also known as AP1GBP1), DDX52, HNF1B, TBC1D3F, TBC1D3, MRPL45, GPR179, SOCS7 and ARHGAP23). Seven of these genes (DUSP14, HNF1B, TBC1D3, TBC1D3F, MRPL45, SOCS7 and ARHGAP23) were overexpressed in EOC cell lines and primary tumors compared to normal tissues ( Fig. 4  and Supplementary Fig. 8 ), indicating that they may have a role in EOC. HNF1B is a strong candidate susceptibility gene at this locus; it has been extensively studied in EOC and is used as a biomarker for subtype stratification of EOC tumors 24 , particularly to distinguish the clear-cell subtype from other EOC subtypes. Consistent with this, overexpression of HNF1B in EOC cell lines was driven largely by higher expression in clear-cell EOC cell lines (Fig. 4) 25 . However, HNF1B shows lower expression in primary serous EOC tissues compared to normal tissues, which may suggest a different role for this gene in clear-cell compared to serous tumors 26 . The phenotypic consequences of HNF1B knockdown in clear-cell EOC cell lines also npg suggest that it may behave as an oncogene in the development of this subtype 27 . We found no correlation between HNF1B expression and DNA copy number variation at this locus in primary EOC tissues, but there was a highly statistically significant inverse correlation between HNF1B expression and methylation (P = 2.1 × 10 −6 ), which implies that the mechanism for overexpression of this gene is epigenetic. RNA sequencing (RNA-seq) analysis of normal ovarian cancer precursor tissues indicates that HNF1B is expressed at extremely low levels ( Fig. 4) , which restricts the extent to which the function of this gene in normal ovarian cancer precursor tissues can be studied. We found no evidence for eQTL association between rs757210 and the expression of any gene in normal tissues throughout the region, but we observed a strong mQTL association between rs757210 and HNF1B methylation (P = 0.009) ( Fig. 4 and Supplementary Table 4 ) in primary serous EOC tissues. The minor (risk) allele of rs757210 was associated with lower methylation and is therefore predicted to be associated with increased HNF1B expression. In the absence of additional functional data, it is difficult to interpret these findings, but, given the possible role of HNF1B as an oncogene in the development of clear-cell ovarian cancer, it may be that increased HNF1B expression at an early stage in the development of ovarian cancer precursor tissues, driven by the risk variant(s) underlying susceptibility, has increased oncogenic activity in the proportion of individuals with serous ovarian cancer who carry this allele.
Overall, the functional data we generated do not point strongly to any one gene at 17q12 as the functionally relevant susceptibility gene. However, when combined with a large body of previous work implicating HNF1B in ovarian cancer development, the data suggest that this gene is the strongest candidate, and the mQTL and methylation-expression associations suggest a mechanism for genetic variants influencing HNF1B expression and disease susceptibility through epigenetic regulation.
DISCUSSION
In this study, we demonstrated the strength of large-scale collaboration in genetic association studies. We have identified three common alleles newly associated with susceptibility to EOC and confirmed two suggestive loci that had been previously reported at near genome-wide significance. Molecular analyses of genes at these loci, combining publicly available data sets and systematic, large-scale experiments, point to a small number of candidate gene targets that may have a role in EOC initiation and development. However, the effects of the new susceptibility loci were modest, and together they explain less than 1% of the excess familial risk of EOC, with about 4% being explained by all known loci with common susceptibility alleles. The lack of heterogeneity between studies of varying designs carried out in different populations and the high levels of statistical significance indicate that these are robust associations. Fewer common susceptibility loci have now been found for EOC than for several other common cancers, including breast, colorectal and prostate cancers 28 . It seems unlikely that the underlying genetic architecture for EOC susceptibility is sub- npg A r t i c l e s stantially different from those of other cancers. This suggests that a key factor limiting our ability to detect susceptibility loci is sample size-the power of this study to detect risk alleles across a range of effect sizes was modest (Supplementary Fig. 12 ). However, EOC is less common than these other cancers and has a higher mortality rate, and recruiting extremely high numbers of cases will be difficult. Disease heterogeneity will also reduce power if a substantial proportion of EOC susceptibility alleles are subtype specific. All EOC susceptibility loci so far identified are strongly associated with serous EOC, which is also the most common subtype. Both the discovery and replication phases of this study were weighted toward identifying risk alleles associated with serous EOC. It seems probable that additional common risk loci for clear-cell, endometrioid and mucinous EOC subtypes also exist and await identification.
Several EOC susceptibility alleles have now been identified that increase the risk of multiple cancers. For example, an increased risk of estrogen receptor-negative breast cancer is associated with the EOC susceptibility allele at 19p13 (refs. 5,29) , and the EOC susceptibility allele at the 17q12 locus reported in this manuscript is also associated with risk of endometrial 22 and prostate cancers 23 . Several of the loci containing EOC susceptibility alleles have been found to harbor different susceptibility alleles for other cancers. For example, Michailidou and colleagues 30 found an association between rs7072776 at 10p12 and breast cancer. This SNP is ~120 kb centromeric to and partially correlated with rs1243180 (r 2 = 0.51). Michailidou and colleagues 30 also report an association of rs11780156 at 8q24 with breast cancer. The new locus lies ~300 kb telomeric of the known locus for ovarian cancer (rs10088218) 6 but is uncorrelated with it (r 2 = 0.02). Both loci lie ~400 kb 3′ of MYC. Previous GWAS have identified multiple loci 5′ of MYC that are associated with different cancer types, including a locus for breast cancer. These associations may reflect the tissue-specific regulation of key genes, and understanding the functional mechanisms underlying genetic associations at the same locus for different phenotypes may provide insights into more general mechanisms of disease etiology and cancer development.
Assuming a log-additive model of interaction between loci, the currently known loci ( Table 2 and Supplementary Table 3 ) define a genetic risk profile with a combined variance for the log relative risk distribution of 0.057. Such a distribution has limited discriminatory ability: the estimated relative risks at the 5th and 95th percentiles are 0.63 and 1.48, respectively. However, on the basis of what is known about the architecture of genetic susceptibility for other cancers, it is probable that many more common susceptibility alleles exist. The discovery of genetic association with ovarian cancer may be enhanced by taking advantage of functional annotation data and the analysis of gene-gene and gene-environment interactions using a genomewide approach. Continued international efforts are needed to establish new case-control studies, expand existing case-control studies and improve the pathological characterization of the cases in these studies to unravel the inherited genetic basis of the disease. In combination with rarer risk alleles and other risk factors, genetic profiling may provide sufficient discrimination to justify targeted ovarian cancer prevention.
URLs. 1000 Genomes Project, http://www.1000genomes.org/page. php/; COSMIC, http://www.sanger.ac.uk/genetics/CGP/cosmic/; GeneMANIA, http://genemania.org/; MACH, http://www.sph.umich. edu/csg/abecasis/MACH/; NCBI Unigene, http://www.ncbi.nlm.nih. gov/unigene; TCGA Project, http://cancergenome.nih.gov/; Cancer Genome Atlas Project data bioportal, http://www.cbioportal.org/; Wellcome Trust Case Control Consortium, http://www.wtccc.org.uk/.
The statistical software programs used are available at http://ccge. medschl.cam.ac.uk/software/.
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